Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prader-Willi syndrome

- PMLiVE

Belviq cleared for US launch after abuse risk determined

Drug Enforcement Administration says Arena's weight loss drug has relatively low risk of abuse

- PMLiVE

Arena pulls obesity drug Belviq application in EU

EMA asks for more data

Vivus launches weight loss app to swell Qsymia sales

iPhone and Android Q and Me app backed up with patient support programme

- PMLiVE

Mixed reaction to Novo Nordisk obesity trial

Analyst says Victoza only has a modest ability to reduce weight in people with diabetes

- PMLiVE

CHMP upholds rejection of Vivus’ obesity drug

Still no recommendation for Qsiva in Europe

- PMLiVE

GSK signs obesity research deal with Vanderbilt University

Follows increased push from pharma to tackle the public health challenge

- PMLiVE

New US Coca-Cola ad while Russia tightens food legislation

Soft drinks giant launches low-cal ad in US while Russia plans tough legislation on fast food advertising and labelling, as pressure on fast food companies grows

- PMLiVE

Takeda ends obesity alliance with Amylin

Comes more than a year after development of lead product was pulled

- PMLiVE

Vivus fails to get European backing for obesity treatment Qsiva

EMA raises concerns about drug’s cardiovascular safety

- PMLiVE

Vivus expects knockback from EMA for obesity drug

Setback comes despite US approval for Qsiva/Qsymia

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links